Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Pluri ( (PLUR) ) is now available.
Pluri has announced a merger with another subsidiary under the same parent company, contingent upon the board of directors’ approval. The merger involves a private offering based on the parent company’s share profitability, and the agreement is set to be formalized today. The company plans to issue a report to the SEC and hold a special shareholders’ meeting on February 25, 2025, where the company’s shares will begin trading on the stock exchange.
More about Pluri
Pluri is a biopharmaceutical company that operates as a subsidiary of Alden, focusing on developing pharmaceutical products. The company is involved in merging with another subsidiary under the control of a parent company, aiming to enhance its market position.
YTD Price Performance: 6.70%
Average Trading Volume: 17,971
Technical Sentiment Consensus Rating: Buy
See more insights into PLUR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue